Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) persists its position slightly strong in context of buying side, while shares price plunged -3.09% during latest trading session.
Merrimack Pharmaceuticals, Inc. (MACK) reported its fourth quarter and full year 2016 financial results for the period ended December 31, 2016. “This is an exciting and important time for Merrimack as we are refocusing into an earlier-stage, R&D-focused biopharmaceutical company,” said Dr. Peters. “The transaction with Ipsen, once completed, will allow for the immediate return of cash to stockholders, while also providing Merrimack with an infusion of capital that we believe will fund our streamlined oncology pipeline into the second half of 2019. We are confident that our clinical stage assets have the potential to benefit cancer patients around the world and drive Merrimack’s long-term success and stockholder value creation.”
Narrow down focus to other ratios, the co has current ratio of 1.00 that indicates if MACK lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 0.80, which indicates firm has sufficient short-term assets to cover its immediate liabilities.
Zions Bancorporation (NASDAQ:ZION) also run on active notice, stock price shows upbeat performance surged 3.63% after traded at $46.53 in most recent trading session.
ZION has price to earnings ratio of 23.16 and the price to current year EPS stands at 66.30%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 19.09%. The earning yield also gives right direction to lure investment, as the co has 0.69% dividend yield. The debt to equity ratio appeared as 0.08 for seeing its liquidity position.
Taking notice on volatility measures, price volatility of stock was 2.08% for a week and 1.98% for a month. The price volatility’s Average True Range for 14 days was 1.03. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 2.40 out of 1-5 scale with week’s performance of 4.00%. ZION’s institutional ownership was registered as 95.60%, while insider ownership was 1.00%.